Deciphera Pharmaceuticals, Inc. (DCPH) Financial Analysis & Valuation | Quarter Chart
Deciphera Pharmaceuticals, Inc. (DCPH)
DCPHPrice: $25.59
Fair Value: 🔒
🔒score
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug can... more
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of... more
Description
Shares
| Market Cap | $2.21B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | Steven L. Hoerter |
| IPO Date | 2017-09-28 | CAGR | — |
| Employees | 355 | Website | www.deciphera.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
DCPH chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.31B | P/E Ratio | -11.58 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 13.55 | P/B Ratio | 6.2 |
| P/CF Ratio | -14.84 | P/FCF Ratio | -15.01 |
| EPS | $-2.21 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 26.51% | Gross Margin | 0.98% |
| Operating Margin | -1.29% | Profit Margin | -1.19% |
| ROE | -0.56% | ROA | -0.41% |
| ROCE | -0.57% | Current Ratio | 3.8 |
| Quick Ratio | 3.59 | Cash Ratio | 0.83 |
| Debt/Equity | 0.07 | Interest Coverage | — |
| Altman Z Score | 7.31 | Piotroski Score | 3 |